SCREENING OF FDA-APPROVED DRUGS AGAINST Giardia lamblia TROPHOZOITES VIABILITY

LAIOLO J.; LUNA PIZARRO, G; FELIZIANI C.; GUANTAY M.B; SORIA G.; ROPOLO A. S.; TOUZ M.C.

Mar del Plata

Congreso; Reunión conjunta SAIC SAB AAFE AACYTAL 2023; 2023

Giardia lamblia is a parasitic protozoan that resides in the small intestine of humans and other vertebrates, causing a disease called giardiasis. Globally, G. lamblia is the third most common cause of diarrheal disease in children under 5 years old, with an estimated 280 million clinical cases worldwide. Due to the increasing resistance of the parasite and the side effects of the standard drugs used in giardiasis treatment, there is a need to search for new therapeutic agents. Thus, the objective of this study was to evaluate The Spectrum Collection library, consisting of drugs approved by the United States Food and Drug Administration (FDA), to identify fast-acting and effective compounds against G. lamblia.